PRESS RELEASE published on 05/15/2024 at 07:30, 5 months 24 days ago Informations privilégiées / Communiqué sur comptes, résultats MaaT Pharma annonce le succès de son offre globale de 19,2 millions d'euros pour financer ses activités de R&D en biotechnologie clinique avancée, incluant des essais cliniques et le développement de son portefeuille thérapeutique Essais Cliniques Offre Globale MaaT Pharma Biotechnologie Clinique Portefeuille Thérapeutique
PRESS RELEASE published on 05/15/2024 at 07:30, 5 months 24 days ago Inside Information / News release on accounts, results MaaT Pharma announces successful completion of 19.2 million euros Global Offering with new shares, aims to fund R&D activities, Phase 3 trials, and broaden pipeline Biotechnology Fundraising Clinical Trials Global Offering MaaT Pharma
BRIEF published on 05/14/2024 at 19:39, 5 months 24 days ago MaaT Pharma Announces 18 Million Euro Global Offering and Strategic Developments Financial Strategy Phase 3 Trial Clinical-stage Biotechnology Global Offering Microbiome Ecosystem Therapies
BRIEF published on 05/14/2024 at 19:39, 5 months 24 days ago MaaT Pharma annonce une offre mondiale et des développements stratégiques de 18 millions d'euros Stratégie Financière Essai De Phase 3 Offre Globale Thérapies Écosystémiques Du Microbiome Biotechnologie Au Stade Clinique
PRESS RELEASE published on 05/14/2024 at 19:34, 5 months 24 days ago Inside Information / News release on accounts, results MaaT Pharma launches a global offering of approximately 18 million euros to fund R&D activities and expand shareholder base. Current shareholders commit to significant subscriptions Global Offering MaaT Pharma 18 Million Euros R&D Activities Shareholder Commitments
PRESS RELEASE published on 05/14/2024 at 19:34, 5 months 24 days ago Informations privilégiées / Communiqué sur comptes, résultats MaaT Pharma lance une augmentation de capital de 18 millions d'euros pour financer ses activités de R&D, incluant des essais cliniques aux États-Unis et en Europe Actionnaires Augmentation De Capital R&D Essais Cliniques MaaT Pharma
Published on 11/08/2024 at 12:00, 23 minutes ago Fusion Energy Agreement Between RSE and BLUE LASER FUSION (USA)
Published on 11/08/2024 at 10:00, 2 hours 23 minutes ago BluSky Carbon CEO Presents a Case for Climate Tech Optimism
Published on 11/08/2024 at 09:00, 3 hours 23 minutes ago Greene Tweed Awarded 'Excellence in International Trade' at the 2024 East Midlands Chamber Business Awards
Published on 11/08/2024 at 07:00, 5 hours 23 minutes ago Polaris Renewable Energy Announces Fixed Income Meetings
Published on 11/08/2024 at 03:00, 9 hours 23 minutes ago Alset AI Appoints Wall Street Veteran and Venture Executive as President
Published on 11/08/2024 at 12:11, 12 minutes ago PNE AG selected by the European Commission for funding a project to produce hydrogen
Published on 11/08/2024 at 12:01, 21 minutes ago EQS-Adhoc: Borussia Dortmund reports preliminary figures for the first quarter (Q1) of the 2024/2025 financial year
Published on 11/08/2024 at 12:01, 22 minutes ago Original-Research: Knaus Tabbert AG (von Montega AG): Kaufen
Published on 11/08/2024 at 11:30, 53 minutes ago Shelly Group: Invitation to unaudited 9M 2024 earnings webcast/call on 14 November 2024
Published on 11/08/2024 at 11:12, 1 hour 11 minutes ago Original-Research: Masterflex SE (von Montega AG): Kaufen
Published on 11/08/2024 at 12:15, 8 minutes ago Louis Hachette Group announces the publication of its Information Document for listing on Euronext Growth (Paris)
Published on 11/08/2024 at 12:15, 8 minutes ago Louis Hachette Group annonce la publication de son Document d’Information en vue de sa cotation sur Euronext Growth (Paris)
Published on 11/08/2024 at 08:00, 4 hours 23 minutes ago DAMARTEX / Droits de vote bruts et réels 31 octobre 2024
Published on 11/07/2024 at 19:00, 17 hours 23 minutes ago ALTAREA : INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
Published on 11/07/2024 at 19:00, 17 hours 23 minutes ago ALTAREA : DECLARATION MENSUELLE DES OPERATIONS REALISEES PAR LA SOCIETE SUR SES PROPRES TITRES OCTOBRE 2024
